Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Diseases of the liver: Chronic liver disease

By Patrick T F Kennedy and John O'Grady

The commonest causes of chronic or end-stage liver disease are alcohol and chronic viral hepatitis. In addition, there are a number of pathways to chronic liver disease, including auto-immune conditions (eg, auto-immune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis) and metabolic conditions (eg, genetic haemochromatosis and Wilson’s disease).

The severity of chronic liver disease is usually assessed by using the Childs-Pugh classification, which is based on five parameters: ascites, encephalopathy, nutritional status, serum albumin, and serum bilirubin. These parameters carry equal weighting towards the total score, with 15 being the highest attainable score (Table 1). The score is then converted into a designation of either Childs-Pugh A (5–6), B (7–9) or C (10–15) for practical purposes, with C representing the most advanced disease. Patients with Childs-Pugh A are often referred to as having compensated cirrhosis, while the presence of overt clinical complications defines the presence of decompensated disease. Renal function is often impaired in chronic liver disease and may be an important factor to consider in drug management.

The management strategy of any liver disease is a combination of treating the symptoms and complications that arise, as well as drug therapies relevant to the specific underlying diagnosis. Encephalopathy, ascites, spontaneous bacterial peritonitis, variceal bleeding and pruritus are the main complications at which drug therapy is directed. The treatment options for specific liver conditions are increasing, especially in the areas of auto-immune and viral disease. The increasing availability and success of liver transplantation has tended to change the emphasis of management, and it is often not appropriate to exhaust other options before referring the patient for a transplant.

The role of specific drugs in the overall management strategy will vary, depending on physician preference and the relative strength of supporting services in individual institutions. An outline of the approach used at King’s College Hospital (KCH) for a number of complications is given. Below is a discussion of the management of pruritus, ascites, spontaneous bacterial peritonitis, encephalopathy and variceal haemorrhage, as well as the various manifestations of chronic liver disease.

Pruritus

Pruritus (itch) is a prominent symptom of cholestatic liver disease. The pathogenesis of pruritus in cholestatic liver disease remains a matter of debate, but therapies that deplete bile acids, as well as centrally acting agents are effective. Antihistamines are relatively ineffective, apart from their sedative effect, and should not be used as first-line therapy.

Colestyramine and colestipol are anionexchange resins which are the usual first-line therapy. These agents act by binding bile acids and preventing their reabsorption. They are insoluble in water, non-absorbable, and are usually taken before meals to maximise the amount of bile acids sequestered. Colestyramine is usually started at a dose of 4g once or twice daily and colestipol as 5g once or twice daily. The dose is titrated to give adequate relief without causing diarrhoea, but pallatability also restricts dosing. These drugs may reduce the absorption of drugs taken at the same time. To avoid this, drugs should be taken one hour before or four hours after colestyramine or colestipol.1 Drugs that are particularly susceptible to the absorption-reducing effect of the nionexchange resins are thyroxine, ursodeoxycholic acid (UDCA), digoxin, propranolol, hydrochlorothiazide, tetracycline and penicillins. Long-term therapy with anion-exchange resins can also cause depletion of the fat-soluble vitamins.

Dowload the attached PDF to read the full article.

Citation: Hospital Pharmacist URI: 10975479

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Pathology and Therapeutics for Pharmacists

    Pathology and Therapeutics for Pharmacists

    An practical, integrated approach to the pathophysiological and pharmacotherapeutic principles underlying the treatment of disease.

    £54.00Buy now
  • Biological Therapeutics

    Biological Therapeutics

    An introduction to the treatment of disease using biological medicines derived from living plant and animal tissues.

    £33.00Buy now
  • Sampson's Textbook of Radiopharmacy

    Sampson's Textbook of Radiopharmacy

    This well-established textbook provides specialised information on the use of radiopharmaceuticals in the detection and treatment of diseases.

    £81.00Buy now
  • Minor Illness or Major Disease

    Minor Illness or Major Disease

    This established textbook helps you differentiate between minor illnesses which can be safely managed in the pharmacy, and major diseases.

    £43.00Buy now
  • Disease Management

    Disease Management

    Disease Management covers the diseases commonly encountered in primary care by system, with common therapeutic issues. Includes case studies and self-assessment sections.

    £54.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary information

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.